Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vernant, J. P.
Right arrow Articles by Reiffers, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vernant, J. P.
Right arrow Articles by Reiffers, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 6, 227-231, Copyright © 1988 by American Society of Clinical Oncology

ARTICLES

Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission

JP Vernant, G Marit, D Maraninchi, D Guyotat, M Kuentz, C Cordonnier and J Reiffers
Service d'hematologie, Hopital Henri Mondor, Creteil, France.

Twenty-seven patients ranging in age from 15 to 36 years participated in a pilot study, and underwent allogeneic bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in first complete remission (CR) in four French centers. All patients were grafted from human leukocyte antigen/mixed leukocyte culture (HLA/MLC) identical sibling after conditioning regimen consisting of cyclophosphamide and total body irradiation (TBI). Sixteen patients are alive in persistent first remission, with a median follow-up of 56 months (range, 41 to 82 months). The 6-year Kaplan-Meier probability of disease-free survival (DFS) is 59%. Only three patients relapsed (5, 7, and 7 months after transplantation). These interesting results have led us to propose, in accord with a French multicentric protocol, allogeneic BMT for adults under 40 years of age during the first CR of ALL.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
T. Girinsky, E. Benhamou, J.-H. Bourhis, F. Dhermain, D. Guillot-Valls, V. Ganansia, M. Luboinski, A. Perez, J. M. Cosset, G. Socie, et al.
Prospective Randomized Comparison of Single-Dose Versus Hyperfractionated Total-Body Irradiation in Patients With Hematologic Malignancies
J. Clin. Oncol., March 1, 2000; 18(5): 981 - 981.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. M. Horowitz, D. Messerer, D. Hoelzer, R. P. Gale, A. Neiss, K. Atkinson, A. J. Barrett, T. Buchner, M. Freund, G. Heil, et al.
Chemotherapy Compared with Bone Marrow Transplantation for Adults with Acute Lymphoblastic Leukemia in First Remission
Ann Intern Med, July 1, 1991; 115(1): 13 - 18.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
N. J. Chao and K. G. Blume
Bone Marrow Transplantation: What Is the Question?
Ann Intern Med, September 1, 1990; 113(5): 340 - 341.
[Abstract] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1988 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online